Search
for
Sort by
Research 30 of 774
- Tofacitinib: The selected selective JAK inhibitor in paediatric dermatology
- 695 Selectively targeting JAK1 or JAK3 pathway is sufficient to reverse alopecia areata
- 170 Forecasting Phase 3 Dose-Response for Abrocitinib, an Oral Janus Kinase 1 Selective Inhibitor, Using Investigator’s Global Assessment and Eczema Area and Severity Index
- Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata
- CS12192 Reverses Alopecia Areata by Selectively Targeting JAK3/JAK1/TBK1.
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
- Sudden improvement of alopecia universalis and psoriatic arthritis while receiving upadacitinib: a case-based review
- Progressive alopecia areata during TNF-α inhibition with intralesional corticosteroid failure and subsequent improvement following JAK1 inhibition
- Emerging Topical and Systemic JAK Inhibitors in Dermatology
- Selective Janus kinase 1 inhibition resolves inflammation and restores hair growth offering a viable treatment option for alopecia areata
- Upadacitinib for the Treatment of Systemic Immune Co-Morbidity in One Case: Alopecia Areata, Vitiligo, Ankylosing Spondylitis, and Allergic Rhinitis-Asthma – Multifaceted Control
- Janus kinase inhibitors for alopecia areata: A narrative review
- JAK1 Signaling Is Involved in the Induction of Mechanical Alloknesis in Atopic Dermatitis
- 33766 Efficacy of baricitinib in patients with various degrees of alopecia areata severity: Results from BRAVE-AA1 and BRAVE-AA2
- 33774 Baricitinib results in eyebrow and eyelash growth in patients with alopecia areata who do not achieve 20% or less scalp hair loss
- Successful treatment of alopecia universalis with abrocitinib: a case report
- Efficacy of Upadacitinib in Treating Alopecia Areata, Atopic Dermatitis, and Th1 Comorbidities in Pediatric Patients: A Comprehensive Case Series and Literature Review
- Abrocitinib Treatment in Diffuse Alopecia Areata: A Case Report and a Literature Review
- Significant improvement with ivarmacitinib after suboptimal response to tofacitinib in severe alopecia areata: a case report and literature review
- Oral abrocitinib for treatment of refractory alopecia areata: A retrospective study
- Upadacitinib in the treatment of a patient with the triad of atopic dermatitis, vitiligo, and alopecia areata: a case report and literature review
- Abrocitinib in the Treatment of Severe Alopecia Areata in a Pediatric Patient: A Case Report
- 0480 Upadacitinib monotherapy for treatment of pyoderma gangrenosum: A case series
- Ivarmacitinib stimulates hair regrowth in severe alopecia areata
- 448 Combined therapeutic approach: Inhibition of MMP-9 and JAK Signaling Synergistically Prevents Depigmentation in Experimental Vitiligo
- P64 Efficacy of baricitinib in patients with different degrees of severe alopecia areata: 52-week results from BRAVE-AA1 and BRAVE-AA2
- Concomitant management of alopecia universalis and ulcerative colitis with upadacitinib
- Treatment of Lichen Planopilaris With Abrocitinib
- Treatment of concomitant alopecia areata and systemic lupus erythematosus with ivarmacitinib: a case report and literature review
- Upadacitinib for management of alopecia areata and rheumatoid arthritis: Letter to the editor